Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration

Nature Communications

Volumn 7, Issue , 2016, Pages

  Smid, Marcel ^a   Rodríguez González, F Germán ^a   Sieuwerts, Anieta M ^a   Salgado, Roberto ^b,c   Prager Van Der Smissen, Wendy J C ^a   Vlugt Daane, Michelle Van Der ^a   Van Galen, Anne ^a   Nik Zainal, Serena ^d,e   Staaf, Johan ^f   Brinkman, Arie B ^g   Van De Vijver, Marc J ^h   Richardson, Andrea L ^i,j   Fatima, Aquila ^a   Berentsen, Kim ^g   Butler, Adam ^d   Martin, Sancha ^d   Davies, Helen R ^d   Debets, Reno ^a   Gelder, Marion E Meijer Van ^a   Van Deurzen, Carolien H M ^a   Macgrogan, Gaëtan ^k   Van Den Eynden, Gert G G M ^b,c   Purdie, Colin ^l   Thompson, Alastair M ^l   Caldas, Carlos ^m   Span, Paul N ⁿ   Simpson, Peter T ^o   Lakhani, Sunil R ^o,p   Van Laere, Steven ^c   Desmedt, Christine ^b   Ringnér, Markus ^f   Tommasi, Stefania ^q   Eyford, Jorunn ^r   Broeks, Annegien ^s   Vincent Salomon, Anne ^t   Futreal, P Andrew ^u   Knappskog, Stian ^v,w   King, Tari ^x   Thomas, Gilles ^y   Viari, Alain ^y,z   Langerød, Anita ^aa,ab   Børresen Dale, Anne Lise ^aa,ab   Birney, Ewan ^ac   Stunnenberg, Hendrik G ^g   Stratton, Mike ^d   Foekens, John A ^a   Martens, John W M ^a   more..

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f LUND UNIVERSITY   (Sweden)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k INSTITUT BERGONIÉ   (France)

^l UNIVERSITY OF DUNDEE   (United Kingdom)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF QUEENSLAND   (Australia)

^p ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^q NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^r UNIVERSITY OF ICELAND   (Iceland)

^s NETHERLANDS CANCER INSTITUTE   (Netherlands)

^t INSTITUT CURIE   (France)

^u UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^v UNIVERSITY OF BERGEN   (Norway)

^w HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^x MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^y CENTRE LÉON BÉRARD   (France)

^z INRIA RHÔNE ALPES   (France)

^aa OSLO UNIVERSITY HOSPITAL   (Norway)

^ab UNIVERSITY OF OSLO   (Norway)

^ac WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTOME; UVOMORULIN;

CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENETIC ANALYSIS; GENOME; IMMUNE RESPONSE; MUTATION; WOMENS HEALTH;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL INFILTRATION; GENE ACTIVITY; GENE MUTATION; GENOMICS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; ONCOGENE; PROTEIN EXPRESSION; RNA SEQUENCE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84989233347     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12910     Document Type: Article

References (43)

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
2. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
3. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
4. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
5. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
6. Paquet, E. R. & Hallett, M. T. Absolute assignment of breast cancer intrinsic molecular subtype. J. Natl Cancer Inst. 107, 357 (2015).
7. Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
8. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
9. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47-54 (2016).
10. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
11. Smid, M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68, 3108-3114 (2008).
12. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
13. Langerod, A. et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast. Cancer Res. 9, R30 (2007).
14. Manie, E. et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69, 663-671 (2009).
15. Usary, J. et al. Mutation of GATA3 in human breast tumors. Oncogene 23, 7669-7678 (2004).
16. Holm, K. et al. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast. Cancer Res. Treat. 133, 583-594 (2012).
17. Roy, P. G. et al. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int. J. Cancer 127, 355-360 (2010).
18. Berx, G. et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14, 6107-6115 (1995).
19. Berx, G. et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13, 1919-1925 (1996).
20. Walerych, D., Napoli, M., Collavin, L. & Del Sal, G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33, 2007-2017 (2012).
21. Leiserson, M. D., Wu, H. T., Vandin, F. & Raphael, B. J. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome. Biol. 16, 160 (2015).
22. Massink, M. P., Kooi, I. E., Martens, J. W., Waisfisz, Q. & Meijers-Heijboer, H. Genomic profiling of CHEK2 and 1100delC-mutated breast carcinomas. BMC Cancer 15, 877 (2015).
23. Lundegaard, C. et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509-W512 (2008).
24. Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007-1017 (2003).
25. Chowell, D. et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8 T cell epitopes. Proc. Natl Acad. Sci. USA 112, E1754-E1762 (2015).
26. Kim, Y., Sidney, J., Pinilla, C., Sette, A. & Peters, B. Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinformatics 10, 394 (2009).
27. Reis-Filho, J. S. & Pusztai, L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378, 1812-1823 (2011).
28. Yu, J. X. et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer 7, 182 (2007).
29. Berns, E. M. et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 52, 1107-1113 (1992).
30. Liao, D. J. & Dickson, R. B. c-Myc in breast cancer. Endocr. Relat. Cancer 7, 143-164 (2000).
31. Olivier, M. et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer. Res. 12, 1157-1167 (2006).
32. Haricharan, S., Bainbridge, M. N., Scheet, P. & Brown, P. H. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res. Treat. 146, 211-220 (2014).
33. van Verschuer, V. M. et al. Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer. Hum. Pathol. 46, 182-190 (2015).
34. Bane, A. L. et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am. J. Surg. Pathol. 31, 121-128 (2007).
35. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
36. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
37. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
38. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998).
39. Goeman, J. J., van de Geer, S. A., de Kort, F. & van Houwelingen, H. C. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20, 93-99 (2004).
40. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
41. Kyte, J. & Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157, 105-132 (1982).
42. McCall, M. N., Bolstad, B. M. & Irizarry, R. A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242-253 (2010).
43. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127 (2007).